Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Developmental therapeutics / investigational immunotherapy

3099 - Clinical activity, safety, and PK/PD from a Phase 1 study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v)


20 Oct 2018


Poster Discussion session - Developmental therapeutics / investigational immunotherapy


Clinical Research;  Cytotoxic Therapy

Tumour Site


Ignacio Melero


Annals of Oncology (2018) 29 (suppl_8): viii133-viii148. 10.1093/annonc/mdy279


I. Melero1, E. Castanon Alvarez2, M. Mau-Sorensen3, U.N. Lassen4, M.P. Lolkema5, D.G. Robbrecht6, C.A. Gomez-Roca7, J. Martin-Liberal8, J. Tabernero9, W. Ros10, S. Ahmed11, N. Isambert12, H. Piper Lepoutre13, C. Boetsch14, J. Charo15, S. Evers16, V. Teichgräber15, J.H.M. Schellens17

Author affiliations

  • 1 Laboratory Of Immunology, Clinica Universitaria de Navarra, 31008 - Pamplona/ES
  • 2 Medical Oncology, Clinica Universitaria de Navarra, 31008 - Pamplona/ES
  • 3 -, SKACCD - Rigshospitalet, 2100 - Copenhagen/DK
  • 4 Finsen Center, Dept. Of Oncology, Phase 1 Unit, Copenhagen University Hospital - Rigshospitalet, 2100 - Copenhagen/DK
  • 5 Medical Oncology, Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 6 Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, 3075 EA - Rotterdam/NL
  • 7 Medical Oncology & Clinical research, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 8 Oncology, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
  • 9 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 10 Medical Oncology, Netherlands Cancer Institute, Amsterdam/NL
  • 11 Leicester Cancer Research Centre, University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, LE1 5WW - Leicester/GB
  • 12 Medical Oncology, Centre Georges-François Leclerc (Dijon), 21079 - Dijon/FR
  • 13 Safety Sciences, Roche Innovation Center Basel, 4070 - Basel/CH
  • 14 Pharmaceutical Sciences, Roche Innovation Center Basel, 4001 - Basel/CH
  • 15 Translational Medicine Oncology, Roche Innovation Center Zurich, 8952 - Schlieren/CH
  • 16 Oncology Dta, Roche Innovation Center Basel, 4001 - Basel/CH
  • 17 Division Of Clinical Pharmacology, Department Of Medical Oncology, The Netherlands Cancer Institute, Amsterdam/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3099


High-dose IL-2 is approved for patients with metastatic melanoma and renal cell carcinoma but is associated with significant toxicity, frequently requiring intensive care. RO6874281 carries an engineered IL2v moiety with abolished binding to IL-2Ra. Affinity to IL-2Rβγ is retained, resulting in activation of immune effector CD8 T and NK lymphocytes, but reduced activity on regulatory T cells (Tregs). The antibody part of RO6874281 binds with high affinity to FAP, which is strongly expressed on tumor-associated fibroblasts, and mediates retention and accumulation in malignant lesions.


Study BP29842 investigates safety, PK/PD and anti-tumor activity of RO6874281, administered i.v. once per week in an outpatient setting to patients with metastatic solid tumors. The dose escalation part enrolled 28 patients with metastatic solid tumors and identified a recommended dose (RD) of 20mg, using one-step intra-patient escalation (15mg followed by 20mg). Patients with treatment refractory melanoma and squamous cell carcinomas are enrolled to an extension cohort to confirm safety and further explore PK/PD and activity of the RD. So far, 16 patients were enrolled to this cohort including 6 with melanoma.


To date, most frequent adverse events (>30%) were pyrexia, infusion related reactions, fatigue/asthenia, nausea, diarrhea, decreased appetite and elevated aspartate and/or alanine transaminase. The majority of events were mild or moderate (Grade 1/ 2). At RD, RO6874281 rapidly expands CD8 and NK cells but not Tregs, both in peripheral blood and sequential tumor biopsies. Objective long-lasting (> 6 months) responses were observed in one patient each with head and neck cancer, penile squamous cell carcinoma and checkpoint inhibitor resistant malignant melanoma across the escalation dose range. Further, tumor shrinkage was observed in 4 melanoma patients, including 1 uveal and 1 mucosal.


RO6874281 is the first targeted IL-2 variant with acceptable outpatient safety to display monotherapy activity, including in tumor types not previously reported to respond to IL-2. Ph1b/Ph2 studies in combination with atezolizumab and other agents are currently underway.

Clinical trial identification

NCT02627274; EudraCT: 2015-002251-97, first posted: December 10, 2015.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.


F. Hoffmann-La Roche Ltd.

Editorial Acknowledgement


H. Piper Lepoutre, C. Boetsch, J. Charo, S. Evers, V. Teichgräber: Employee with stock options: F. Hoffmann-La Roche Ltd. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.